Institutional members access full text with Ovid®

Share this article on:

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

Schulman, Sam*†; Kearon, Clive*; Kakkar, Ajay K.; Schellong, Sebastian§; Eriksson, Henry; Baanstra, David; Kvamme, Anne Mathilde#; Friedman, Jeffrey**; Mismetti, Patrick††; Goldhaber, Samuel Z.‡‡For the RE-MEDY and the RE-SONATE Trials Investigators

doi: 10.1097/01.SA.0000433313.08275.7d
Miscellaneous

*Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; †Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; ‡Thrombosis Research Institute and University College London, London, United Kingdom; §Medical Division 2, Municipal Hospital Friedrichstadt, Dresden, Germany; ∥Department of Medicine, Sahlgrenska University Hospital-Östra, Gothenburg, Sweden; ¶Clinical Research, Boehringer Ingelheim, Alkmaar, the Netherlands; #Clinical Research Boehringer Ingelheim, Asker, Norway; **Boehringer Ingelheim, Ridgefield, CT; ††Department of Vascular Pathology, Bellevue Hospital, Saint Etienne, France; and ‡‡Brigham and Women’s Hospital and Harvard Medical School, Boston, MA.

© 2013 Lippincott Williams & Wilkins